BioCentury | Mar 6, 2014
Tools & Techniques

Taking TIMP3 to heart

A U.S. team has found a way to harness the cardioprotective activity of tissue inhibitor of metalloproteinases 3 while avoiding its off-target effects by embedding it in a hydrogel for direct injection into the heart....
BioCentury | Feb 6, 2014
Distillery Therapeutics

Indication: Infectious disease

...Licensing status Publication and contact information Infectious disease Tuberculosis Mycobacterium tuberculosis membrane protein MmpS4 (mmpS4); mmpS5...
...vitro studies suggest inhibiting siderophore secretion in M. tuberculosis could help treat tuberculosis. MmpS4 and mmpS5...
...for M. tuberculosis siderophore export, which facilitates iron scavenging. In M. tuberculosis, mutant mmpS4 and mmpS5...
BioCentury | Nov 21, 2013
Targets & Mechanisms

Getting to the root of periodontitis

Current periodontitis therapies do not target the underlying immune response that drives the disease. A team from the U.S. and Brazil is looking to change that and has shown that microparticles loaded with chemokine CC...
BioCentury | Feb 4, 2013
Emerging Company Profile

Incanthera: Using, not targeting, MMP

Incanthera Ltd. has found a new use for a class of enzymes that are up-regulated in tumors and contribute to cancer progression. Rather than design inhibitors of matrix metalloproteinases , the biotech is instead using them...
BioCentury | Jun 28, 2012
Targets & Mechanisms

Fragmentary progress in endometriosis

A team from the Baylor College of Medicine has treated endometriosis in mice by blocking a pathway that produces a fragment of nuclear receptor coactivator 1 in endometrial tissue. 1 Now, small molecule inhibitors are...
BioCentury | Jun 21, 2012
Distillery Techniques

Technology: Drug delivery

Approach Summary Licensing status Publication and contact information Drug delivery Vaginal delivery of antiviral-loaded mucus-penetrating particles (MPPs) Vaginal delivery of antiviral-loaded MPPs could be used to prevent viral infections. In mice receiving intravaginal delivery of...
BioCentury | Jun 18, 2012
Emerging Company Profile

Armour: Relaxin in CRPC

Armour Therapeutics Inc. 's relaxin receptor antagonists may provide a complementary hormonal therapy that can be given either with or after anti-androgen therapy in prostate cancer patients. Targeting a secondary pathway alongside an androgen pathway...
BioCentury | Apr 12, 2012
Targets & Mechanisms

DEL1: taking the bite out of periodontitis

An international team of researchers has used the endothelial protein DEL1 to treat periodontitis in mice. 1 Despite the therapeutic angle, the near-term utility of DEL1 is more likely to be as a diagnostic and...
BioCentury | Nov 10, 2011
Targets & Mechanisms

Countering chemo-induced metastasis

Two independent research teams have elucidated mechanisms by which cisplatin and paclitaxel can promote lung metastases in mice, providing links between the chemotherapies and the known metastatic effects of upregulating VEGF receptor 1 and matrix...
BioCentury | Jun 23, 2011
Targets & Mechanisms

A bid to revive MMP inhibitors

Matrix metalloproteinases , or MMPs, were once viewed as obvious drug targets-extracellular proteases that are selectively upregulated and play critical functional roles in many diseases. But MMP inhibitors failed in cancer trials a decade ago primarily...
Items per page:
1 - 10 of 63